Director Shareholding

Cambridge Antibody Tech Group PLC 19 May 2005 SCHEDULE 11 NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS 1) Name of company Cambridge Antibody Technology 2) Name of director John Stocker 3) Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of a non-beneficial interest or in the case of an individual holder if it is a holding of that person's spouse or children under the age of 18 or in respect of a non-beneficial interest As in 2 above 4) Name of the registered holder(s) and, if more than one holder, the number of shares held by each of them (if notified) Greenwood Nominees Limited 5) Please state whether notification relates to a person(s) connected with the Director named in 2 above and identify the connected person(s) As in 2 above 6) Please state the nature of the transaction. For PEP transactions please indicate whether general/single co PEP and if discretionary/non discretionary Quarterly payment of part of directors fees in lieu of cash consideration (see notes at 23) 7) Number of shares/amount of stock acquired 274 8) Percentage of issued class 0.0005% 9) Number of shares/amount of stock disposed Nil 10) Percentage of issued class Nil 11) Class of security Ordinary 10 pence shares 12) Price per share £5.69 13) Date of transaction 19 May 2005 14) Date company informed 19 May 2005 15) Total holding following this notification 82,460 16) Total percentage holding of issued class following this notification 0.160 If a director has been granted options by the company please complete the following boxes 17) Date of grant 18) Period during which or date on which exercisable 19) Total amount paid (if any) for grant of the option 20) Description of shares or debentures involved: class, number 21) Exercise price (if fixed at time of grant) or indication that price is to be fixed at time of exercise 22) Total number of shares or debentures over which options held following this notification 23) Any additional information The practice of issuing shares in lieu of part of the basic directors fee has been established by the Company for some time. In November 2004 the Board resolved that such issue of shares would occur on a quarterly rather than an annual basis. The share price used is the average closing price of one CAT share for the three trading days preceding 19 May 2005. 24) Name of contact and telephone number for queries Justin Hoskins, 01223 898589 25) Name and signature of authorised company official responsible for making this notification Date of Notification..19 May 2005 SCHEDULE 11 NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS 1) Name of company Cambridge Antibody Technology 2) Name of director Ake Stavling 3) Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of a non-beneficial interest or in the case of an individual holder if it is a holding of that person's spouse or children under the age of 18 or in respect of a non-beneficial interest As in 2 above 4) Name of the registered holder(s) and, if more than one holder, the number of shares held by each of them (if notified) Greenwood Nominees Limited 5) Please state whether notification relates to a person(s) connected with the Director named in 2 above and identify the connected person(s) As in 2 above 6) Please state the nature of the transaction. For PEP transactions please indicate whether general/single co PEP and if discretionary/non discretionary Quarterly payment of part of directors fees in lieu of cash consideration (see notes at 23) 7) Number of shares/amount of stock acquired 274 8) Percentage of issued class 0.0005% 9) Number of shares/amount of stock disposed Nil 10) Percentage of issued class Nil 11) Class of security Ordinary 10 pence shares 12) Price per share £5.69 13) Date of transaction 19 May 2005 14) Date company informed 19 May 2005 15) Total holding following this notification 2,616 16) Total percentage holding of issued class following this notification 0.005% If a director has been granted options by the company please complete the following boxes 17) Date of grant 18) Period during which or date on which exercisable 19) Total amount paid (if any) for grant of the option 20) Description of shares or debentures involved: class, number 21) Exercise price (if fixed at time of grant) or indication that price is to be fixed at time of exercise 22) Total number of shares or debentures over which options held following this notification 23) Any additional information The practice of issuing shares in lieu of part of the basic directors fee has been established by the Company for some time. In November 2004 the Board resolved that such issue of shares would occur on a quarterly rather than an annual basis. The share price used is the average closing price of one CAT share for the three trading days preceding 19 May 2005. 24) Name of contact and telephone number for queries Justin Hoskins, 01223 898589 25) Name and signature of authorised company official responsible for making this notification Date of Notification..19 May 2005 SCHEDULE 11 NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS 1) Name of company Cambridge Antibody Technology 2) Name of director Sir Aaron Klug 3) Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of a non-beneficial interest or in the case of an individual holder if it is a holding of that person's spouse or children under the age of 18 or in respect of a non-beneficial interest As in 2 above 4) Name of the registered holder(s) and, if more than one holder, the number of shares held by each of them (if notified) Greenwood Nominees Limited 5) Please state whether notification relates to a person(s) connected with the Director named in 2 above and identify the connected person(s) As in 2 above 6) Please state the nature of the transaction. For PEP transactions please indicate whether general/single co PEP and if discretionary/non discretionary Quarterly payment of part of directors fees in lieu of cash consideration (see notes at 23) 7) Number of shares/amount of stock acquired 274 8) Percentage of issued class 0.0005% 9) Number of shares/amount of stock disposed Nil 10) Percentage of issued class Nil 11) Class of security Ordinary 10 pence shares 12) Price per share £5.69 13) Date of transaction 19 May 2005 14) Date company informed 19 May 2005 15) Total holding following this notification 28,201 16) Total percentage holding of issued class following this notification 0.055% If a director has been granted options by the company please complete the following boxes 17) Date of grant 18) Period during which or date on which exercisable 19) Total amount paid (if any) for grant of the option 20) Description of shares or debentures involved: class, number 21) Exercise price (if fixed at time of grant) or indication that price is to be fixed at time of exercise 22) Total number of shares or debentures over which options held following this notification 23) Any additional information The practice of issuing shares in lieu of part of the basic directors fee has been established by the Company for some time. In November 2004 the Board resolved that such issue of shares would occur on a quarterly rather than an annual basis. The share price used is the average closing price of one CAT share for the three trading days preceding 19 May 2005. 24) Name of contact and telephone number for queries Justin Hoskins, 01223 898589 25) Name and signature of authorised company official responsible for making this notification Date of Notification..19 May 2005 SCHEDULE 11 NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS 1) Name of company Cambridge Antibody Technology 2) Name of director Peter Ringrose 3) Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of a non-beneficial interest or in the case of an individual holder if it is a holding of that person's spouse or children under the age of 18 or in respect of a non-beneficial interest As in 2 above 4) Name of the registered holder(s) and, if more than one holder, the number of shares held by each of them (if notified) Greenwood Nominees Limited 5) Please state whether notification relates to a person(s) connected with the Director named in 2 above and identify the connected person(s) As in 2 above 6) Please state the nature of the transaction. For PEP transactions please indicate whether general/single co PEP and if discretionary/non discretionary Quarterly payment of part of directors fees in lieu of cash consideration (see notes at 23) 7) Number of shares/amount of stock acquired 274 8) Percentage of issued class 0.0005% 9) Number of shares/amount of stock disposed Nil 10) Percentage of issued class Nil 11) Class of security Ordinary 10 pence shares 12) Price per share £5.69 13) Date of transaction 19 May 2005 14) Date company informed 19 May 2005 15) Total holding following this notification 3,436 16) Total percentage holding of issued class following this notification 0.007% If a director has been granted options by the company please complete the following boxes 17) Date of grant 18) Period during which or date on which exercisable 19) Total amount paid (if any) for grant of the option 20) Description of shares or debentures involved: class, number 21) Exercise price (if fixed at time of grant) or indication that price is to be fixed at time of exercise 22) Total number of shares or debentures over which options held following this notification 23) Any additional information The practice of issuing shares in lieu of part of the basic directors fee has been established by the Company for some time. In November 2004 the Board resolved that such issue of shares would occur on a quarterly rather than an annual basis. The share price used is the average closing price of one CAT share for the three trading days preceding 19 May 2005. 24) Name of contact and telephone number for queries Justin Hoskins, 01223 898589 25) Name and signature of authorised company official responsible for making this notification Date of Notification..19 May 2005 SCHEDULE 11 NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS 1) Name of company Cambridge Antibody Technology 2) Name of director Professor Christopher Marshall 3) Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of a non-beneficial interest or in the case of an individual holder if it is a holding of that person's spouse or children under the age of 18 or in respect of a non-beneficial interest As in 2 above 4) Name of the registered holder(s) and, if more than one holder, the number of shares held by each of them (if notified) Greenwood Nominees Limited 5) Please state whether notification relates to a person(s) connected with the Director named in 2 above and identify the connected person(s) As in 2 above 6) Please state the nature of the transaction. For PEP transactions please indicate whether general/single co PEP and if discretionary/non discretionary Quarterly payment of part of directors fees in lieu of cash consideration (see notes at 23) 7) Number of shares/amount of stock acquired 274 8) Percentage of issued class 0.0005% 9) Number of shares/amount of stock disposed Nil 10) Percentage of issued class Nil 11) Class of security Ordinary 10 pence shares 12) Price per share £5.69 13) Date of transaction 19 May 2005 14) Date company informed 19 May 2005 15) Total holding following this notification 501 16) Total percentage holding of issued class following this notification 0.001% If a director has been granted options by the company please complete the following boxes 17) Date of grant 18) Period during which or date on which exercisable 19) Total amount paid (if any) for grant of the option 20) Description of shares or debentures involved: class, number 21) Exercise price (if fixed at time of grant) or indication that price is to be fixed at time of exercise 22) Total number of shares or debentures over which options held following this notification 23) Any additional information The practice of issuing shares in lieu of part of the basic directors fee has been established by the Company for some time. In November 2004 the Board resolved that such issue of shares would occur on a quarterly rather than an annual basis. The share price used is the average closing price of one CAT share for the three trading days preceding 19 May 2005. 24) Name of contact and telephone number for queries Justin Hoskins, 01223 898589 25) Name and signature of authorised company official responsible for making this notification Date of Notification..19 May 2005 SCHEDULE 11 NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS 1) Name of company Cambridge Antibody Technology 2) Name of director Dr Paul Nicholson 3) Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of a non-beneficial interest or in the case of an individual holder if it is a holding of that person's spouse or children under the age of 18 or in respect of a non-beneficial interest As in 2 above 4) Name of the registered holder(s) and, if more than one holder, the number of shares held by each of them (if notified) Dr Paul Nicholson 5) Please state whether notification relates to a person(s) connected with the Director named in 2 above and identify the connected person(s) As in 2 above 6) Please state the nature of the transaction. For PEP transactions please indicate whether general/single co PEP and if discretionary/non discretionary Quarterly payment of part of directors fees in lieu of cash consideration (see notes at 23) 7) Number of shares/amount of stock acquired 659 8) Percentage of issued class 0.0013% 9) Number of shares/amount of stock disposed Nil 10) Percentage of issued class Nil 11) Class of security Ordinary 10 pence shares 12) Price per share £5.69 13) Date of transaction 19 May 2005 14) Date company informed 19 May 2005 15) Total holding following this notification 10,269 16) Total percentage holding of issued class following this notification 0.019% If a director has been granted options by the company please complete the following boxes 17) Date of grant 18) Period during which or date on which exercisable 19) Total amount paid (if any) for grant of the option 20) Description of shares or debentures involved: class, number 21) Exercise price (if fixed at time of grant) or indication that price is to be fixed at time of exercise 22) Total number of shares or debentures over which options held following this notification 23) Any additional information The practice of issuing shares in lieu of part of the basic directors fee has been established by the Company for some time. In November 2004 the Board resolved that such issue of shares would occur on a quarterly rather than an annual basis. The share price used is the average closing price of one CAT share for the three trading days preceding 19 May 2005. 24) Name of contact and telephone number for queries Justin Hoskins, 01223 898589 25) Name and signature of authorised company official responsible for making this notification Date of Notification..19 May 2005 SCHEDULE 11 NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS 1) Name of company Cambridge Antibody Technology 2) Name of director Professor Uwe Bicker 3) Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of a non-beneficial interest or in the case of an individual holder if it is a holding of that person's spouse or children under the age of 18 or in respect of a non-beneficial interest As in 2 above 4) Name of the registered holder(s) and, if more than one holder, the number of shares held by each of them (if notified) Professor Uwe Bicker 5) Please state whether notification relates to a person(s) connected with the Director named in 2 above and identify the connected person(s) As in 2 above 6) Please state the nature of the transaction. For PEP transactions please indicate whether general/single co PEP and if discretionary/non discretionary Quarterly payment of part of directors fees in lieu of cash consideration (see notes at 23) 7) Number of shares/amount of stock acquired 274 8) Percentage of issued class 0.0005% 9) Number of shares/amount of stock disposed Nil 10) Percentage of issued class Nil 11) Class of security Ordinary 10 pence shares 12) Price per share £5.69 13) Date of transaction 19 May 2005 14) Date company informed 19 May 2005 15) Total holding following this notification 6,319 16) Total percentage holding of issued class following this notification 0.012% If a director has been granted options by the company please complete the following boxes 17) Date of grant 18) Period during which or date on which exercisable 19) Total amount paid (if any) for grant of the option 20) Description of shares or debentures involved: class, number 21) Exercise price (if fixed at time of grant) or indication that price is to be fixed at time of exercise 22) Total number of shares or debentures over which options held following this notification 23) Any additional information The practice of issuing shares in lieu of part of the basic directors fee has been established by the Company for some time. In November 2004 the Board resolved that such issue of shares would occur on a quarterly rather than an annual basis. The share price used is the average closing price of one CAT share for the three trading days preceding 19 May 2005. 24) Name of contact and telephone number for queries Justin Hoskins, 01223 898589 25) Name and signature of authorised company official responsible for making this notification Date of Notification..19 May 2005 This information is provided by RNS The company news service from the London Stock Exchange
UK 100

Latest directors dealings